Session Overview The FDA’s Risk Evaluation and Mitigation Strategy (REMS) for mifepristone allows patients to obtain the drug without an in-person visit to a clinician. Ongoing federal litigation has challenged the FDA’s REMS for mifepristone, seeking to add or remove restrictions. In the meantime, mifepristone access is being undermined by additional restrictions at the state...